NCT07766005 A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
| NCT ID | NCT07766005 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Spyre Therapeutics, Inc. |
| Condition | Hidradenitis Suppurativa (HS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-09 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 150 participants in total. It began in 2026-09 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of Hidradenitis Suppurativa with symptoms for at least 6 months before screening. * Hidradenitis suppurativa lesions in at least 2 distinct anatomical areas, with at least 1 area meeting Hurley Stage II or III criteria at screening and Day 1. * Total abscess and/or inflammatory nodule count of at least 5 at screening and Day 1. * Documented inadequate response, intolerance, or contraindication to at least 1 systemic therapy for hidradenitis suppurativa. Exclusion Criteria: * More than 20 draining tunnels at screening or Day 1. * Hidradenitis suppurativa lesion expected to require incision and drainage within 4 weeks before Day 1, or major hidradenitis suppurativa surgery within 12 weeks before Day 1. * Another inflammatory or skin condition that could interfere with assessment of hidradenitis suppurativa.
Contact & Investigator
Joshua Friedman, MD, PhD
STUDY DIRECTOR
Spyre Therapeutics, Inc.
Frequently Asked Questions
Who can join the NCT07766005 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hidradenitis Suppurativa (HS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07766005 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07766005 currently recruiting?
Yes, NCT07766005 is actively recruiting participants. Contact the research team at info@SKYLIGHT-trial.com for enrollment information.
Where is the NCT07766005 trial being conducted?
This trial is being conducted at Birmingham, United States, Rogers, United States, Irvine, United States, Coral Gables, United States and 11 additional locations.
Who is sponsoring the NCT07766005 clinical trial?
NCT07766005 is sponsored by Spyre Therapeutics, Inc.. The principal investigator is Joshua Friedman, MD, PhD at Spyre Therapeutics, Inc.. The trial plans to enroll 150 participants.